Sify.com » Topics » Amylin
Amylin News
Summary Box: Lilly receives restraining order
: Amylin Pharmaceuticals Inc. said Thursday a federal court issued an injunction preventing drug development partner Eli Lilly and Co. from using the same sales force to sell an Amylin-developed type 2 diabetes treatment, Byetta, and Boehringer Ingelheim's Tradjenta.REACTION: Lilly said it was disappointed in the decision but will comply with the order.THE BIG PICTURE: Amylin and Lilly entered an agreement
: Amylin Pharmaceuticals Inc. said Thursday a federal court issued an injunction preventing drug development partner Eli Lilly and Co. from using the same sales force to sell an Amylin-developed type 2 diabetes treatment, Byetta, and Boehringer Ingelheim's Tradjenta.REACTION: Lilly said it was disappointed in the decision but will comply with the order.THE BIG PICTURE: Amylin and Lilly entered an agreement
Court issues restraining order against Eli Lilly
Amylin Pharmaceuticals Inc. said Thursday a federal court issued an injunction preventing drug development partner Eli Lilly and Co. from using the same sales force to sell an Amylin-developed
Amylin 1Q loss narrows on lower costs
Amylin Pharmaceuticals reported that its first-quarter loss narrowed as it spent less on both its sales force and on research and development.
Amylin Pharmaceuticals reported that its first-quarter loss narrowed as it spent less on both its sales force and on research and development.
Clarification: Amylin FDA info request story
In a story March 15, The Associated Press reported that Bydureon is the proposed trade name of exenatide, a diabetes treatment being developed by Amylin Pharmaceuticals Inc., Eli Lilly&Co. and
Amylin shares up on FDA response for diabetes drug
Shares of Amylin Pharmaceuticals jumped 13 percent Monday as the Food and Drug Administration asked for more information on its potential diabetes treatment.
Shares of Amylin Pharmaceuticals jumped 13 percent Monday as the Food and Drug Administration asked for more information on its potential diabetes treatment.
FDA asks for risk plan info on diabetes drug
Amylin Pharmaceuticals Inc. said Monday it received a Food and Drug Administration request for information on manufacturing and a risk mitigation plan for a potential once-weekly diabetes treatment.
Amylin Pharmaceuticals Inc. said Monday it received a Food and Drug Administration request for information on manufacturing and a risk mitigation plan for a potential once-weekly diabetes treatment.
© Copyright Sify Technologies Ltd, 1998-2011. All rights reserved. India News Portal, Sify.com hosted at SifyHosting India's first Level 3 Internet Data Centre.
Site optimized for Internet Explorer 5.5 and above.
See Disclaimer |Privacy Policy &Parental Guidance on pornography |careers@sify |About Us |Feedback |Advertise
Site optimized for Internet Explorer 5.5 and above.
See Disclaimer |Privacy Policy &Parental Guidance on pornography |careers@sify |About Us |Feedback |Advertise